{"entity":{"id":"nct06416410","kind":"trial","name":"JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation","aka":[],"tldr":"A phase 3 trial testing Sitneprotafib in non-small-cell lung cancer, now recruiting.","summary":"JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation is a phase 3 interventional study registered as NCT06416410, led by Allist Pharmaceuticals, and recruiting on the registry. Official title: An Open-label, Randomised, Positive Control, Multicenter Phase III Clinical Study. Evaluating JAB-21822 Combined With JAB-3312 Compared Tislelizumab Combined With Pemetrexed + Carboplatin in the First Line for Treatment of Advanced Non-squamous Non-small Cell Lung Cancer With KRAS p.G12C Mutation. Planned enrolment is 392 participants (estimated). The study started in 2024-08-07 and primary completion is expected in 2029-09-30. No results have been posted on ClinicalTrials.gov.","status":"recruiting","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov NCT06416410","url":"https://clinicaltrials.gov/study/NCT06416410"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","kras-g12c-nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["sitneprotafib"],"companies":["allist"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06416410","phase":"3","setting":"An Open-label, Randomized, Positive Control, Multicenter Phase III Clinical Study. Evaluating JAB-21822 Combined With JAB-3312 Compared Tislelizumab Combined With Pemetrexed + Carboplatin in the First Line for Treatment of Advanced Non-squamous Non-small Cell Lung Cancer With KRAS p.G12C Mutation","sponsor":"Allist Pharmaceuticals","started":"2024-08-07","startedType":"actual","enrolled":392,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06416410/","neighbours":{"cancer":[{"id":"kras-g12c-nsclc","kind":"cancer","name":"KRAS G12C-mutant non-small-cell lung cancer","route":"/cancers/kras-g12c-nsclc/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"drug":[{"id":"glecirasib","kind":"drug","name":"Glecirasib","route":"/drugs/glecirasib/"},{"id":"sitneprotafib","kind":"drug","name":"Sitneprotafib","route":"/drugs/sitneprotafib/"}],"company":[{"id":"allist","kind":"company","name":"Shanghai Allist Pharmaceuticals","route":"/companies/allist/"}]}}